fulvestrant   Click here for help

GtoPdb Ligand ID: 1015

Synonyms: Faslodex® | ICI 182,780 | ICI 182780 | ICI182780 | ZD-9238
Approved drug
fulvestrant is an approved drug (FDA (2002), EMA (2004))
Compound class: Synthetic organic
Comment: Fulvestrant is an estrogen receptor antagonist. It behaves as a selective estrogen receptor degrader (SERD). Fulvestrant binding triggers ERα's degradation by ubiquitination.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 15
Topological polar surface area 76.74
Molecular weight 606.32
XLogP 10.2
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=S(CCCC(C(F)(F)F)(F)F)CCCCCCCCCC1Cc2cc(O)ccc2C2C1C1CCC(C1(CC2)C)O
Isomeric SMILES O=S(CCCC(C(F)(F)F)(F)F)CCCCCCCCC[C@@H]1Cc2cc(O)ccc2[C@@H]2[C@@H]1[C@@H]1CC[C@@H]([C@]1(CC2)C)O
InChI InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
InChI Key VWUXBMIQPBEWFH-WCCTWKNTSA-N
No information available.
Summary of Clinical Use Click here for help
Fulvestrant is used to treat hormone receptor-positive (HR +ve) metastatic breast cancer in post-menopausal women. In September 2017, fulvestrant was FDA approved as a first-line monotherapy for HR +ve, HER2 -ve advanced breast cancer in endocrine-therapy näive, post-menopausal women. Due to its poor pharmacokinetic properties in humans (low solubility and bioavailability and high metabolism) fulvestrant has to be administered as monthly intramuscular injections.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Fulvestrant binds to estrogen receptors present in cancer cells and leads to receptor desensitisation and degradation, such that estrogen-responsiveness is lost and the cancer cells die.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)